# Upcycle framing for MtF weight cycling

This file is the practical "how to upcycle" synthesis for the MtF weight-cycling use case. It is a companion to the downcycle half of the cycle in `research/selective-fat-redistribution/_summary.md`. The central question is: *given a feminised hormone milieu, does deliberate weight gain bias new adipose toward gluteofemoral / breast depots enough to matter, and what practical pattern makes that most likely?*

Summary in one sentence: the mechanistic biology is reasonably well established (estradiol promotes adipogenesis and blunts lipolysis in gluteofemoral fat; testosterone does the opposite), but the downstream claim that repeated weight cycling materially accelerates body reshaping in MtF individuals on HRT has no peer-reviewed outcome evidence — it rests on mechanism plus Powers/mesityl anecdote. Treat it as plausible, not proven, and optimize the cycle for what won't hurt you if the reshaping effect is small.

---

**Claim:** In a feminised hormone milieu (estradiol-dominant, androgens suppressed), newly deposited subcutaneous fat is biologically biased toward the gluteofemoral depot relative to the abdominal depot — in premenopausal women, LPL activity is higher in gluteofemoral than abdominal fat; estradiol administration to postmenopausal women increases LPL-mediated lipid accumulation specifically in the gluteofemoral depot; and estrogens increased adipogenesis from gluteofemoral but not abdominal adipose-derived stem cells in postmenopausal women.
- **Confidence:** C2
- **Sources:** https://pmc.ncbi.nlm.nih.gov/articles/PMC7921847/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC3411490/ ; https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21133 ; https://www.sciencedirect.com/topics/medicine-and-dentistry/sexual-dimorphism-of-obesity (Palmer & Clegg 2015, Mol Cell Endocrinol)
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** The three canonical references are Palmer & Clegg 2015 ("The sexual dimorphism of obesity"), Karastergiou et al. 2012 ("Sex differences in human adipose tissues — the biology of pear shape"), and Fried/Lee/Karastergiou 2015 (Obesity). Direction of effect is well supported; effect size on a timescale of weeks-to-months during a single upcycle is not quantified in humans.

**Claim:** In MtF individuals on estrogen-based gender-affirming hormone therapy, fat genuinely redistributes toward the gluteofemoral region over 12 months — subcutaneous fat area increased ~84% at the hip (mean +60 cm²) and ~84% at thigh (mean +80 cm²) after 12 months of estrogen therapy in a prospective multicentre study, alongside smaller increases in total subcutaneous and visceral fat and a decline in muscle mass.
- **Confidence:** C2
- **Sources:** https://pubmed.ncbi.nlm.nih.gov/29183889/ ; https://academic.oup.com/jcem/article/107/1/e153/6355699 ; https://journals.physiology.org/doi/full/10.1152/ajpendo.1999.276.2.E317 (Elbers et al. 1999, AJP Endocrinology)
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** Direction and rough magnitude are consistent across Elbers 1999 (the original MRI study in transsexuals), the 2017 ENIGI multicentre cohort (Klaver et al.), and 2022 JCEM analyses. HRT alone produces gluteofemoral gain over 12 months *without* any cycling intervention; this is the background against which any added upcycle effect has to be detected.

**Claim:** Weight cycling as a deliberate tool to accelerate gynoid redistribution in MtF individuals has no peer-reviewed evidence base. The argument is mechanistic (estradiol promotes adipogenesis in gluteofemoral depots, testosterone inhibits it; therefore every gain cycle under feminised hormones is a fresh biasing opportunity) plus anecdotal (Dr Will Powers' clinical writing, mesityl's 2022 post, scattered forum reports). The mesityl post itself acknowledges "we have no peer-reviewed evidence for this theory."
- **Confidence:** C4
- **Sources:** https://mesityl.substack.com/p/mtf-weight-cycling ; https://blog.darkarts.wiki/p/an-introduction-to-fat-redistribution (2026-04-12 intro post)
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** C4 because the load-bearing claim — that repeated cycles shift body shape faster than HRT alone at the same final weight — is unfalsified and uncontrolled. Adipocyte turnover is ~10%/year with half-replacement around 8.3 years (Spalding et al. 2008 Nature), but intracellular lipid turnover is much faster (~1.6 years), so the timescale over which cycling could plausibly act is the lipid-turnover timescale, not the cell-turnover timescale. Practical implication: the effect, if real, is probably small over 1-3 cycles and demands that the cycling *itself* doesn't cause harm larger than the reshaping gain.

**Claim:** The "calorie-dense fat + modest carbs to trigger insulin-mediated fat deposition" heuristic that mesityl and forum culture propose for upcycling is only partly supported by mainstream nutrition science. De novo lipogenesis from dietary carbohydrate is low on a normal mixed diet (3-8 g/d of fat synthesised from carbs in overfeeding studies, vs. 60-75 g/d of body fat storage per day total); excess energy is stored as fat regardless of whether the surplus comes from fat or carbohydrate, because dietary fat is stored with minimal metabolic cost while carbohydrate is preferentially oxidised. The insulin-spike framing is therefore partial and somewhat speculative; the robust claim is simply "energy-dense, palatable, easy-to-overconsume foods make hitting a surplus easier."
- **Confidence:** C2
- **Sources:** https://pubmed.ncbi.nlm.nih.gov/11722954/ ; https://ajcn.nutrition.org/article/S0002-9165(23)06404-3/fulltext ; https://pubmed.ncbi.nlm.nih.gov/10365981/ ; https://pubmed.ncbi.nlm.nih.gov/3165600/ (Acheson 1988 on glycogen-ceiling DNL)
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** Acheson 1988 is the outlier: massive carbohydrate overfeeding (~5000 kcal/d for days) saturates glycogen stores (~500 g) and then drives meaningful DNL. Under that regime, insulin-driven fat deposition is real. Under normal eating (even aggressive bulking at +500-1000 kcal), glycogen does not saturate and DNL stays low. Mesityl's heuristic is not *wrong* — calorie-dense fat plus some carbs is a reasonable food pattern for hitting a surplus — but the mechanism as stated ("insulin drives fat deposition, so spike insulin") is folk-endocrinology; body fat storage is primarily a matter of total energy balance plus depot-level hormone signalling.

**Claim:** Alcohol is specifically discouraged during an MtF upcycle because it (a) preferentially promotes visceral / abdominal adiposity in women, and (b) raises circulating androgens (testosterone, androstenedione, DHEAS) in both pre- and postmenopausal women. In a 2024 meta-analysis, per 10 g/d alcohol was associated with ~4.3% higher total testosterone in premenopausal women and ~2.8% higher in postmenopausal women, with positive associations to androstenedione and DHEAS. An IJO 2026 analysis reported >10% higher proportional visceral fat mass in women consuming >10 units/week, independent of total fat mass.
- **Confidence:** C2
- **Sources:** https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35391 (Tin Tin 2024 meta-analysis + Mendelian randomization) ; https://www.nature.com/articles/s41366-026-02030-5 (IJO 2026) ; https://pubmed.ncbi.nlm.nih.gov/2266338/ (Kiefer et al. 1990, fat distribution and steroid hormones in women with alcohol abuse)
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** The androgen-raising effect is the specifically MtF-relevant part: for someone who has suppressed androgens as a core of their transition, adding an agent that reliably nudges androgens back up *and* biases fat toward the abdomen is the opposite of the upcycle goal. The visceral-fat effect is dose-dependent; light infrequent drinking is likely benign, but "moderate" daily drinking is already in the range where effects are measurable. Counterpoint: in some epidemiology, frequent low-intensity drinking shows smaller abdominal height than non-drinking (Dorn 2003), so the signal is dominated by *bingeing* and *dose*. The conservative MtF-upcycle recommendation is still "near-zero during the gain phase."

**Claim:** A conservative practical upcycle pattern that fits the evidence is: modest energy surplus (~+300-500 kcal/day, roughly +0.25-0.5% bodyweight/week), calorie-dense whole-food choices (nuts, olive oil, full-fat dairy, peanut butter, oats, dried fruit) rather than candy/alcohol, adequate protein (~1.6-2.2 g/kg if any resistance training is being done), duration of several months per cycle rather than days, and near-zero alcohol. This pattern is borrowed directly from the lean-bulking literature (which has RCT-level support for surplus size and p-ratio) grafted onto the MtF-specific rationale (avoid abdominal-biased choices, avoid androgen-raising inputs).
- **Confidence:** C3
- **Sources:** https://pmc.ncbi.nlm.nih.gov/articles/PMC6710320/ (Slater 2019 on surplus size) ; https://pmc.ncbi.nlm.nih.gov/articles/PMC10620361/ (Ribeiro 2023 surplus trial) ; See c001, c002, c003 in this folder for the background lean-bulking evidence.
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** C3 (inferred) because the specific application to MtF upcycling is not tested; the underlying surplus-size, protein-target, and p-ratio claims are well supported. Duration is a judgement call: mesityl recommends 2-3 cycles total and not more, citing diminishing returns and mental strain; the scientific basis for "how long should one upcycle last" is absent. A 3-6 month upcycle gaining 3-7 kg, then a downcycle of similar duration, is the most commonly described pattern in MtF communities.

**Claim:** Resistance training choices during an MtF upcycle are theoretically relevant but not empirically settled. Generic hypertrophy dose-response (10-20 hard sets/muscle/week, 2+ sessions/week, progressive overload) is well established; the MtF-specific question — "does glute-biased, upper-body-light lifting preferentially channel the surplus into lower-body lean mass and, by local blood flow / substrate preference, lower-body fat?" — has no human trial. The plausibility argument is: training a muscle increases its local blood flow, substrate uptake, and surrounding adipose activity, so heavier glute/hamstring/thigh work *might* nudge both lean and fat gains toward the lower body. This is mechanistic speculation, not evidence.
- **Confidence:** C4
- **Sources:** https://pubmed.ncbi.nlm.nih.gov/27433992/ (Schoenfeld volume meta-analysis) ; https://pmc.ncbi.nlm.nih.gov/articles/PMC9528903/ (Plotkin 2022 progression) ; See c003 for detailed training claims. For the selective-fat-exercise question: the spot-reduction literature is null on meta-analysis (see selective-fat-redistribution/_summary.md and its c014/c015), with two small positive matched-EE local-plus-cardio trials (Brobakken 2023; Paoli 2021) suggesting a marginal hedge, not a real lever.
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** Practical advice: train everything with a modest glute/hamstring/thigh-biased volume tilt. The reasonable claim is "more lower-body lean mass = more hip/thigh circumference directly from muscle," which is straightforwardly true and visible regardless of whether fat partitioning responds. Upper-body training is not contraindicated; excessive upper-body emphasis that produces very visible trap/shoulder/arm hypertrophy may counteract the desired silhouette.

**Claim:** Honest caveats for anyone considering a deliberate upcycle as a transition tool: (1) the peer-reviewed evidence that cycling accelerates redistribution beyond what HRT alone achieves is essentially absent — the clean comparator study does not exist; (2) weight cycling in general population data is associated with small increases in type-2 diabetes risk (RR ~1.23) and possibly other metabolic signals, though the causal status is contested and the MtF subpopulation is unstudied; (3) intentional weight gain followed by loss is psychologically demanding and can precipitate or worsen disordered eating; (4) the reshaping ceiling is limited by adipocyte biology (half-replacement ~8.3 years for the cells themselves, ~1.6 years for stored lipid), so huge gains from a few cycles over a single year are implausible; (5) the MtF protocol that can be defended is the one that *also* keeps you healthy if the redistribution bonus turns out to be zero.
- **Confidence:** C3
- **Sources:** https://mesityl.substack.com/p/mtf-weight-cycling ; https://pubmed.ncbi.nlm.nih.gov/18272894/ (Spalding 2008 Nature, adipocyte turnover) ; https://pubmed.ncbi.nlm.nih.gov/25921103/ (weight cycling and diabetes risk meta-analysis) ; Cross-ref: `research/selective-fat-redistribution/_summary.md`.
- **Date checked:** 2026-04-14
- **Cross-verified:** yes
- **Notes:** This claim is a synthesis across the evidence map rather than a single-source finding, hence C3. The final bullet is the practical framing: design the upcycle so that it is a defensible lean-bulking protocol on its own terms (modest surplus, whole foods, resistance training, adequate sleep, no alcohol, no sketchy drugs) — that way the downside is bounded if the fat-redistribution bonus fails to materialise.

---

## Cross-references

- Downcycle half of the cycle: `research/selective-fat-redistribution/_summary.md`.
- Lean-bulk base rates: `c001-diet-structure-surplus-and-rate.md`, `c002-calorie-dense-foods-and-insulin.md`, `c003-resistance-training-for-lean-mass.md`, `c012-protein-leucine-arginine.md`.
- Low-value / dangerous bin: `c015-low-value-hype-and-dangerous.md`.
- Topical adipogenesis agents (hexapeptide-38, volufiline, etc.) are covered in `c010-topical-local-adipogenesis.md` and should be cross-linked here for readers looking for "direct" biasing tools rather than systemic strategies.
- Pioglitazone, the single most-endorsed systemic tool in mesityl's write-up, is out of scope for this claim file but belongs in the weight-gain-methods medication track.

## Open questions flagged to `tasks/human-tasks.md`

- No controlled human trial of MtF weight cycling vs. HRT-only matched on final weight and hormone exposure exists; any future research agent doing a fresh literature pass should search PubMed for "transgender" + "weight cycling" / "weight gain" / "body composition" / "fat distribution" with a post-2025 cutoff in case a registry analysis has appeared.
- Mesityl cites a specific alcohol-and-androgens paper; the strongest modern replacements are Tin Tin 2024 (cancer meta-analysis with Mendelian randomization) and Kiefer 1990. Older mesityl citation (unavailable) could not be verified directly.